PCSK9 inhibition: A game changer in cholesterol management - Mayo Clinic
Nov 20, 2015 · Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) plays an important role in cholesterol metabolism by regulating LDL receptor degradation. Shortly after its discovery in 2001, the gene encoding PCSK9 was implicated in …
PCSK9 inhibitors: Pharmacology, adverse effects, and use
Oct 8, 2024 · Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes. Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C).
Repatha: Uses, Dosage & Side Effects - Drugs.com
Sep 25, 2023 · Repatha (evolocumab) is a PCSK9 inhibitor used for hypercholesterolemia (high cholesterol) and cardiovascular risk reduction. Includes Repatha side effects, interactions and indications.
Evolocumab and Clinical Outcomes in Patients with …
May 4, 2017 · Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%.
REPATHA is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to...
Evolocumab - Wikipedia
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often colloquially referred to as "bad" cholesterol, from the blood. [7] [8]
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 …
Evolocumab (REPATHA ®, Amgen, Inc.) is a human monoclonal immunoglobulin G2 (IgG2) that binds specifically to human PCSK9 to inhibit its effects on LDLR, resulting in reduction of LDL-C.
filled syringe, single-use prefilled autoinjector, or single-use on-body infusor with pre. have been reported in patients treated with REPATHA, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions …
REPATHA- evolocumab injection, solution REPATHA- evolocumab kit - DailyMed
Aug 20, 2024 · REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: in adults with established cardiovascular disease (CVD) to reduce the risk of myocardial infarction, stroke, and coronary revascularization
How does Repatha work? - Drugs.com
Feb 5, 2024 · Repatha (evolocumab) is a monoclonal antibody that works by inhibiting PCSK9 (proprotein convertase subtilisin kexin type 9). PCSK9 is a protein found in the liver that plays a key role in plasma cholesterol metabolism.